Recruitment

Recruitment Status
Completed
Estimated Enrollment
30

Inclusion Criterias

parent's and child's primary language is English or Spanish
child is between 5-11 years
child received a clinical diagnosis of ADHD
...
parent's and child's primary language is English or Spanish
child is between 5-11 years
child received a clinical diagnosis of ADHD
child does not take any other medication on a regular basis (like every day)
child is receiving stimulant medication for the first time

Exclusion Criterias

any chronic medical condition that requires on-going medication management
moderate-severe developmental delays, mental retardation or autism
prescription of combined psychotropic medication
any chronic medical condition that requires on-going medication management
moderate-severe developmental delays, mental retardation or autism
prescription of combined psychotropic medication

Summary

Conditions
Attention Deficit Disorder With Hyperactivity
Type
Observational
Design
  • Observational Model: Case-Only
  • Time Perspective: Prospective

Participation Requirements

Age
Between 5 years and 12 years
Gender
Both males and females

Description

In other words, the study will find out whether it is feasible and acceptable for parents to receive reminders for clinic visits and ADHD medication and enter daily ratings of their child's ADHD symptoms and medication side effects into a smart phone. It will also examine whether it is feasible and ...

In other words, the study will find out whether it is feasible and acceptable for parents to receive reminders for clinic visits and ADHD medication and enter daily ratings of their child's ADHD symptoms and medication side effects into a smart phone. It will also examine whether it is feasible and acceptable for doctors to use this information summarized on a tablet (iPad) screen during a medication follow-up visit. If the parent consents, the study will also examine whether it is feasible and acceptable for the child's teacher to enter their ratings of ADHD symptoms twice a week using a link on their email. This information will also be included in the doctor's iPad screen. If this technology is found to be promising, then a larger study will be done to examine if medication treatment is safer, more consistent, and more effective using this technology compared to usual care. This is important because the technology may remove the burden on parents and teachers to report ADHD symptoms and medication side effects using paper forms, and for doctors to record this information in the medical record. In total, there will be 12 parent/ child dyads, 6 clinicians and up to 12 teachers enrolled. Each parent/child dyad will be videotaped for up to 3 visits with the clinician (n=36 videotaped sessions). The study time period is from the first visit that ADHD medication is prescribed to the time of the third follow-up medication visit. We anticipate that the follow-up visits will be every 1-2 weeks during this early phase of stimulant medication treatment. Thus, the study time period for each parent/child dyad will be between 4-8 weeks. We anticipate that data collection will occur between August 19, 2013 and June 31, 2014.

Inclusion Criterias

parent's and child's primary language is English or Spanish
child is between 5-11 years
child received a clinical diagnosis of ADHD
...
parent's and child's primary language is English or Spanish
child is between 5-11 years
child received a clinical diagnosis of ADHD
child does not take any other medication on a regular basis (like every day)
child is receiving stimulant medication for the first time

Exclusion Criterias

any chronic medical condition that requires on-going medication management
moderate-severe developmental delays, mental retardation or autism
prescription of combined psychotropic medication
any chronic medical condition that requires on-going medication management
moderate-severe developmental delays, mental retardation or autism
prescription of combined psychotropic medication

Locations

Los Angeles, California, 90095
Los Angeles, California, 90059
Northridge, California, 91325
Los Angeles, California, 90095
Los Angeles, California, 90059
Northridge, California, 91325

Tracking Information

NCT #
NCT01990222
Collaborators
Not Provided
Investigators
  • Principal Investigator: Bonnie Zima, MD, MPH University of California, Los Angeles
  • Bonnie Zima, MD, MPH University of California, Los Angeles